Comparison
While Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880, Snap-8 is a cosmetic peptide studied for reducing wrinkle depth by inhibiting synaptic vesicle fusion and subsequent muscle contraction in facial expression muscles5060.
While Liraglutide works as a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880, Snap-8 is acetyl octapeptide-3 (Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2), an extended analog of Argireline derived from the N-terminal region of SNAP-25 that competes with native SNAP-25 for binding to syntaxin-1, forming a non-functional SNARE complex and reducing neurotransmitter release5060.
Liraglutide is 31 amino acids long, whereas Snap-8 is shorter as it has a length of 8 amino acids. Liraglutide is made up of a sequence of sequence data not available in the current dataset. Snap-8 is made up of a sequence of Glutamic acid, Glutamic acid, Methionine, Glutamine, Arginine, Arginine, Alanine, Aspartic acid.
Liraglutide
GCG
Snap-8
Not assigned in the current dataset.